These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36585434)

  • 1. MyProstateScore in men considering repeat biopsy: validation of a simple testing approach.
    Tosoian JJ; Sessine MS; Trock BJ; Ross AE; Xie C; Zheng Y; Samora NL; Siddiqui J; Niknafs Y; Chopra Z; Tomlins S; Kunju LP; Palapattu GS; Morgan TM; Wei JT; Salami SS; Chinnaiyan AM
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):563-567. PubMed ID: 36585434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    Tosoian JJ; Trock BJ; Morgan TM; Salami SS; Tomlins SA; Spratt DE; Siddiqui J; Kunju LP; Botbyl R; Chopra Z; Pandian B; Eyrich NW; Longton G; Zheng Y; Palapattu GS; Wei JT; Niknafs YS; Chinnaiyan AM
    J Urol; 2021 Mar; 205(3):732-739. PubMed ID: 33080150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
    Tosoian JJ; Zhang Y; Xiao L; Xie C; Samora NL; Niknafs YS; Chopra Z; Siddiqui J; Zheng H; Herron G; Vaishampayan N; Robinson HS; Arivoli K; Trock BJ; Ross AE; Morgan TM; Palapattu GS; Salami SS; Kunju LP; Tomlins SA; Sokoll LJ; Chan DW; Srivastava S; Feng Z; Sanda MG; Zheng Y; Wei JT; Chinnaiyan AM;
    JAMA Oncol; 2024 Jun; 10(6):726-736. PubMed ID: 38635241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need.
    Tosoian JJ; Singhal U; Davenport MS; Wei JT; Montgomery JS; George AK; Salami SS; Mukundi SG; Siddiqui J; Kunju LP; Tooke BP; Ryder CY; Dugan SP; Chopra Z; Botbyl R; Feng Y; Sessine MS; Eyrich NW; Ross AE; Trock BJ; Tomlins SA; Palapattu GS; Chinnaiyan AM; Niknafs YS; Morgan TM
    Urology; 2022 Jun; 164():184-190. PubMed ID: 34906585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study.
    Tosoian JJ; Dunn RL; Niknafs YS; Saha A; Vince RA; St Sauver JL; Jacobson DJ; McGree ME; Siddiqui J; Groskopf J; Jacobsen SJ; Tomlins SA; Kunju LP; Morgan TM; Salami SS; Wei JT; Chinnaiyan AM; Sarma AV
    Eur Urol Open Sci; 2021 Jul; 29():30-35. PubMed ID: 34337531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
    McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
    BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    Sanda MG; Feng Z; Howard DH; Tomlins SA; Sokoll LJ; Chan DW; Regan MM; Groskopf J; Chipman J; Patil DH; Salami SS; Scherr DS; Kagan J; Srivastava S; Thompson IM; Siddiqui J; Fan J; Joon AY; Bantis LE; Rubin MA; Chinnayian AM; Wei JT; ; Bidair M; Kibel A; Lin DW; Lotan Y; Partin A; Taneja S
    JAMA Oncol; 2017 Aug; 3(8):1085-1093. PubMed ID: 28520829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.
    Eyrich NW; Wei JT; Niknafs YS; Siddiqui J; Ellimoottil C; Salami SS; Palapattu GS; Mehra R; Kunju LP; Tomlins SA; Chinnaiyan AM; Morgan TM; Tosoian JJ
    Urol Oncol; 2022 Jan; 40(1):4.e1-4.e7. PubMed ID: 34753659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.
    Robinson HS; Lee SS; Barocas DA; Tosoian JJ
    Prostate Cancer Prostatic Dis; 2024 Jun; ():. PubMed ID: 38858447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies.
    De Luca S; Passera R; Cappia S; Bollito E; Randone DF; Milillo A; Papotti M; Porpiglia F
    BJU Int; 2014 Dec; 114(6b):E56-E61. PubMed ID: 24472071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A; Okihara K; Kamoi K; Oikawa T; Shimazui T; Murayama S; Tomita K; Umekawa T; Uemura H; Miki T
    BJU Int; 2013 May; 111(6):928-33. PubMed ID: 23331404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
    Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
    Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
    Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
    J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
    Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
    Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.